Immutep Ltd TACTI-002 Clinical Results & Update Global Webcast Transcript
Good morning, everyone. Thank you for joining us for another Immutep investor call. Today, we're going to discuss the recent and upcoming clinical results from the company's lead product candidate, Eftilagimod Alpha. Clive Tompkins here, I'll be your moderator today. At this time, all participants are in listen-only mode. There will be a Q&A session at the end of the conference. This time, we will be taking questions from analysts and questions that have been submitted ahead of time.
I'd now like to hand you over to Marc Voigt, Immutep CEO, to start the presentation. Thanks, Marc.
Yes. Thank you, Clive, and welcome, everyone. We very much appreciate everyone's time on the call today with us. Here is our usual forward-looking statement. And today, we are very, very excited to take you through the new data from our TACTI-002 clinical trial and talk about the broader clinical program for our lead product candidate,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
